Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | F10 | P00742 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.37 |
| ▸ | JAK1 | P23458 | 4/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 3/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.35 |
| ▸ | BDKRB1 | P46663 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.35 |
| ▸ | SMO | Q99835 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL784116 | 0.94 | F10 (0.37) | F10JAK2JAK1CCR5MCHR1 | |
| SCHEMBL785223 | 0.91 | F10 (0.43) | F10RAB9ANPC1USP30 | |
| SCHEMBL785808 | 0.91 | F10 (0.39) | LCKF10JAK2JAK1CCR5 | |
| SCHEMBL785958 | 0.90 | F10 (0.38) | LCKF10JAK2JAK1RAB9A | |
| SCHEMBL785416 | 0.87 | HPGD (0.44) | F10CCR5MCHR1BDKRB1USP30 | |
| SCHEMBL785154 | 0.87 | HPGD (0.44) | F10CCR5MCHR1BDKRB1USP30 | |
| SCHEMBL785803 | 0.87 | USP30 (0.45) | F10JAK2JAK1RAB9AUSP30 | |
| SCHEMBL784348 | 0.85 | F10 (0.39) | F10JAK2JAK1CCR5MCHR1 | |
| SCHEMBL785496 | 0.84 | F10 (0.39) | F10CCR5MCHR1BDKRB1USP30 | |
| SCHEMBL785511 | 0.84 | TAS1R3 (0.52) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | claimed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | claimed |
| US-8680159-B2 | Bradykinin 1 receptor modulating compounds | GRUENENTHAL GMBH (DE) | 2014-03-25 | — | — | US | disclosed |
| US-20120071461-A1 | Substituted Benzamide Compounds | GRUENENTHAL GMBH (DE) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071461-A1 | Substituted Benzamide Compounds | BDKRB1, BDKRB2, HRH2 | LCK 2969/4885F10 524/4885JAK2 1298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.